Spire Wealth Management Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Spire Wealth Management grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,079 shares of the company's stock after acquiring an additional 2,200 shares during the quarter. Spire Wealth Management's holdings in Eli Lilly and Company were worth $19,535,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company during the third quarter worth approximately $36,000. Family CFO Inc bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $40,000. Finally, O Brien Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company's stock valued at $44,000 after purchasing an additional 31 shares during the period. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

LLY has been the topic of a number of research reports. Barclays raised their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an "overweight" rating in a research report on Wednesday, February 7th. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a "neutral" rating in a report on Thursday, April 11th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an "overweight" rating in a research report on Tuesday, February 6th. Bank of America boosted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. Finally, Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a "buy" rating in a research report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

NYSE LLY traded down $20.94 during trading hours on Friday, reaching $734.97. The company's stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The company's 50-day moving average is $761.06 and its two-hundred day moving average is $672.28. The firm has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company's revenue was up 26.0% compared to the same quarter last year. During the same period last year, the firm posted $1.62 earnings per share. On average, equities analysts predict that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.